Grand Pharmaceutical acquires 17.8% stake in InnovHeart and rights to Saturn device

Grand Pharmaceutical Group will acquire approximately 17.8% equity of InnovHeart and obtain exclusive rights to the Saturn mitral valve replacement device in Greater China for €43.8 million.

“The Group will acquire approximately 17.8% equity interests of InnovHeart and obtain the exclusive development, manufacturing and commercialization rights of Saturn”grandpharm.com

• 1 source
• grandpharm.comGP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn - Company - News Center - Grand Pharma GroupNov 28, 2021

Summarized from public sources; check the original articles before acting on it.